Therapeutic response in musculoskeletal soft tissue sarcomas: Evaluation by MRI

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 750-763

  Wang, Xin ^a   Jacobs, Michael A ^b   Fayad, Laura ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MRI; Musculoskeletal; Response; Sarcoma; Soft tissue; Therapy; Treatment; Tumor

Indexed keywords

MUSCULOSKELETAL; RESPONSE; SARCOMA; SOFT TISSUE; THERAPY; TREATMENT;

TUMORS;

MAGNETIC RESONANCE IMAGING;

CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL;

ANGIOSARCOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURGERY; CONTRAST ENHANCED MRI; CONVENTIONAL T1 AND T2 WEIGHTED IMAGING; CRYOTHERAPY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; HYPERTHERMIC THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

HUMANS; MAGNETIC RESONANCE IMAGING; MUSCULOSKELETAL SYSTEM; SARCOMA; TREATMENT OUTCOME;

EID: 79960824185     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1731     Document Type: Review

References (156)

1. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon; 2002.
2. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch. Pathol. Lab. Med. 2006; 130(10): 1448-1453.
3. de Saint Aubain Somerhausen N, Fletcher CD. Soft-tissue sarcomas: an update. Eur. J. Surg. Oncol. 1999; 25(2): 215-220.
4. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol. 1997; 15(1): 350-362.
5. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, Vilain MO, Jacquemier J, Duplay H, Sastre X, Barlier C, Henry-Amar M, Mace-Lesech J, Contesso G. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol. 1996; 14(3): 869-877.
6. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982; 49(8): 1721-1733.
7. Welker JA, Henshaw RM, Jelinek J, Shmookler BM, Malawer MM. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer 2000; 89(12): 2677-2686.
8. Yang J, Frassica FJ, Fayad L, Clark DP, Weber KL. Analysis of nondiagnostic results after image-guided needle biopsies of musculoskeletal lesions. Clin. Orthop. Relat. Res. 2010; 468(11): 3103-3111.
9. Skubitz KM, D'Adamo DR. Sarcoma. Mayo Clin. Proc. 2007; 82(11): 1409-1432.
10. De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J. Magnetic resonance imaging of soft tissue tumors. Eur. Radiol. 2000; 10(2): 213-223.
11. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, Shungu DC, Shim H. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis. Markers 2003; 19(2-3): 69-94.
12. Warburg O. The Metabolism of Tumor. Constable&Co. Ltd.: London; 1930.
13. Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed. 2002; 15(2): 114-119.
14. Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, Van Der Sanden B. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2000; 2(1-2): 139-151.
15. 1H MRSI. Magn. Reson. Med. 1999; 41(4): 743-750.
16. Sostman HD, Prescott DM, Dewhirst MW, Dodge RK, Thrall DE, Page RL, Tucker JA, Harrelson JM, Reece G, Leopold KA. MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 1994; 190(1): 269-275.
17. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996; 56(5): 941-943.
18. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 1998; 46(3): 229-237.
19. Exton JH. Signaling through phosphatidylcholine breakdown. J. Biol. Chem. 1990; 265(1): 1-4.
20. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycles. Trends Biochem. Sci. 1989; 14(1): 28-30.
21. Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin. Musculoskelet. Radiol. 2007; 11(3): 240-245.
22. Fayad LM, Barker PB, Jacobs MA, Eng J, Weber KL, Kulesza P, Bluemke DA. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. Am. J. Roentgenol. 2007; 188(6): 1513-1520.
23. Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J. Magn. Reson. Imaging 2006; 23(1): 23-28.
24. Fayad LM, Salibi N, Wang X, Machado AJ, Jacobs MA, Bluemke DA, Barker PB. Quantification of muscle choline concentrations by proton MR spectroscopy at 3T: technical feasibility. Am. J. Roentgenol. 2010; 194(1): W73-W79.
25. Fayad LM, Wang X, Salibi N, Barker PB, Jacobs MA, Machado AJ, Weber KL, Bluemke DA. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. Am. J. Roentgenol. 2010; 195(1): W69-W75.
26. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59(1): 80-84.
27. Gill SS, Thomas DG, Van Bruggen N, Gadian DG, Peden CJ, Bell JD, Cox IJ, Menon DK, Iles RA, Bryant DJ. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J. Comput. Assist. Tomogr. 1990; 14(4): 497-504.
28. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem. Rev. 2010; 110(5): 3043-3059.
29. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 45(3): 459-466.
30. Mukherji SK, Schiro S, Castillo M, Kwock L, Muller KE, Blackstock W. Proton MR spectroscopy of squamous cell carcinoma of the extracranial head and neck: in vitro and in vivo studies. Am. J. Neuroradiol. 1997; 18(6): 1057-1072.
31. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209(1): 269-275.
32. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104(2): 361-366.
33. Robinson D, Yassin M, Nevo Z. Cryotherapy of musculoskeletal tumors - from basic science to clinical results. Technol. Cancer Res. Treat. 2004; 3(4): 371-375.
34. Marcove RC, Miller TR. The treatment of primary and metastatic localized bone tumors by cryosurgery. Surg. Clin. North Am. 1969; 49(2): 421-430.
35. Hazle JD, Stafford RJ, Price RE. Magnetic resonance imaging-guided focused ultrasound thermal therapy in experimental animal models: correlation of ablation volumes with pathology in rabbit muscle and VX2 tumors. J. Magn. Reson. Imaging 2002; 15(2): 185-194.
36. Jacobs MA, Herskovits EH, Kim HS. Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery - preliminary study. Radiology 2005; 236(1): 196-203.
37. Jolesz FA, Hynynen K, McDannold N, Tempany C. MR imaging-controlled focused ultrasound ablation: a noninvasive image-guided surgery. Magn. Reson. Imaging Clin. N. Am. 2005; 13(3): 545-560.
38. Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Ehrenstein T, Shushan A, Hindley JT, Goldin RD, David M, Sklair M, Rabinovici J. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am. J. Obstet. Gynecol. 2003; 189(1): 48-54.
39. Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, Wang ZB. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med. Biol. 2002; 28(4): 535-542.
40. Vanel D, Shapeero L, Guinebretiere J, Genin J. Posttreatment assessment of soft tissue tumors. In: De Schepper A (ed.). Imaging of Soft Tissue Tumors. Springer: Berlin, Heidelberg, New York; 1997, pp. 113-126.
41. Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologie 1983; 4(3): 135-141.
42. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J. Cancer Res. Clin. Oncol. 1983; 106(Suppl): 21-24.
43. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92(3): 205-216.
44. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer 2006; 42(8): 1031-1039.
45. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008; 13(Suppl 2): 32-40.
46. Jaffe CC. Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist 2008; 13(Suppl 2): 14-18.
47. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG. High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009; 251(2): 447-456.
48. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13(Suppl 2): 4-7.
49. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45(2): 228-247.
50. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50(Suppl 1): 122S-150S.
51. Siegel MJ. Magnetic resonance imaging of musculoskeletal soft tissue masses. Radiol. Clin. North Am. 2001; 39(4): 701-720.
52. McSweeney MB, Small WC, Cerny V, Sewell W, Powell RW, Goldstein JH. Magnetic resonance imaging in the diagnosis of breast disease: use of transverse relaxation times. Radiology 1984; 153(3): 741-744.
53. Merchant TE, Thelissen GR, de Graaf PW, Nieuwenhuizen CW, Kievit HC, Den Otter W. Application of a mixed imaging sequence for MR imaging characterization of human breast disease. Acta Radiol. 1993; 34(4): 356-361.
54. Wu JS, Hochman MG. Soft-tissue tumors and tumorlike lesions: a systematic imaging approach. Radiology 2009; 253(2): 297-316.
55. Richardson ML, Lough LR, Shuman WP, Lazerte GD, Conrad EU. MR appearance of skeletal neoplasms following cryotherapy. Skeletal Radiol. 1994; 23(2): 121-125.
56. Ilaslan H, Sundaram M. Advances in musculoskeletal tumor imaging. Orthop. Clin. North Am. 2006; 37(3): 375-391, vii.
57. Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology 1987; 164(1): 243-245.
58. Biondetti PR, Ehman RL. Soft-tissue sarcomas: use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging. Radiology 1992; 183(3): 845-848.
59. Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, O'Kennedy R. Molecular and magnetic resonance imaging: the value of immunoliposomes. Adv. Drug Deliv. Rev. 2009; 61(15): 1402-1411.
60. Anzai Y. Superparamagnetic iron oxide nanoparticles: nodal metastases and beyond. Top. Magn. Reson. Imaging 2004; 15(2): 103-111.
61. Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. Am. J. Roentgenol. 1999; 172(5): 1347-1351.
62. Vanel D, Shapeero LG, Tardivon A, Western A, Guinebretiere JM. Dynamic contrast-enhanced MRI with subtraction of aggressive soft tissue tumors after resection. Skeletal Radiol. 1998; 27(9): 505-510.
63. Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin. Orthop. Relat. Res. 1997; 337: 216-225.
64. Bartolozzi C, Lencioni R, Caramella D, Mazzeo S, Ciancia EM. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging. Am. J. Roentgenol. 1994; 162(4): 827-831.
65. Castrucci M, Sironi S, De Cobelli F, Salvioni M, Del Maschio A. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom. Imaging 1996; 21(6): 488-494.
66. Murakami T, Nakamura H, Hori S, Tomoda K, Mitani T, Nakanishi K, Hashimoto T, Tsuda K, Kozuka T, Monden M, Wakasa K. Detection of viable tumor cells in hepatocellular carcinoma following transcatheter arterial chemoembolization with iodized oil. Pathologic correlation with dynamic turbo-FLASH MR imaging with Gd-DTPA. Acta Radiol. 1993; 34(4): 399-403.
67. Feydy A, Anract P, Tomeno B, Chevrot A, Drape JL. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. Radiology 2006; 238(2): 611-621.
68. Lin C, Luciani A, Belhadj K, Deux JF, Kuhnowski F, Maatouk M, Beaussart P, Cuenod CA, Haioun C, Rahmouni A. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 2010; 254(2): 521-531.
69. Gupta H, Weissleder R. Targeted contrast agents in MR imaging. Magn. Reson. Imaging Clin. North Am. 1996; 4(1): 171-184.
70. Strijkers GJ, Mulder WJ, van Heeswijk RB, Frederik PM, Bomans P, Magusin PC, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 2005; 18(4): 186-192.
71. 2 relaxivity. Magn. Reson. Med. 2009; 61(5): 1022-1032.
72. Castillo M, Arbelaez A, Smith JK, Fisher LL. Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases. Am. J. Neuroradiol. 2000; 21(5): 948-953.
73. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, Junck L, Taylor JM, Johnson TD, Dong Q, Muraszko KM, Brunberg JA, Ross BD. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol. Imaging 2002; 1(4): 336-343.
74. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl. Cancer Inst. 2000; 92(24): 2029-2036.
75. Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, Bluemke DA. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 2010; 256(1): 64-73.
76. Herneth AM, Friedrich K, Weidekamm C, Schibany N, Krestan C, Czerny C, Kainberger F. Diffusion weighted imaging of bone marrow pathologies. Eur. J. Radiol. 2005; 55(1): 74-83.
77. 23Na) MRI of uterine leiomyomata after MR-guided high-intensity focused ultrasound: a preliminary study. J. Magn. Reson. Imaging 2009; 29(3): 649-656.
78. Jacobs MA, Pan L, Macura KJ. Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer. Semin. Roentgenol. 2009; 44(2): 111-122.
79. Jin G, An N, Jacobs MA, Li K. The role of parallel diffusion-weighted imaging and apparent diffusion coefficient (ADC) map values for evaluating breast lesions: preliminary results. Acad. Radiol. 2010; 17(4): 456-463.
80. 2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn. Reson. Med. 1991; 18(1): 39-50.
81. 2-weighted and magnetic susceptibility-enhanced MR imaging in cats. Am. J. Neuroradiol. 1990; 11(3): 423-429.
82. Babsky AM, Topper S, Zhang H, Gao Y, James JR, Hekmatyar SK, Bansal N. Evaluation of extra- and intracellular apparent diffusion coefficient of sodium in rat skeletal muscle: effects of prolonged ischemia. Magn. Reson. Med. 2008; 59(3): 485-491.
83. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168(2): 497-505.
84. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161(2): 401-407.
85. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn. Reson. Med. 1995; 33(5): 697-712.
86. Jacobs MA, Ouwerkerk R, Wolff AC, Stearns V, Bottomley PA, Barker PB, Argani P, Khouri N, Davidson NE, Bhujwalla ZM, Bluemke DA. Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol. Cancer Res. Treat. 2004; 3(6): 543-550.
87. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2006; 17(3): 505-512.
88. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J. Magn. Reson. Imaging 2004; 20(4): 654-661.
89. Herneth AM, Philipp MO, Naude J, Funovics M, Beichel RR, Bammer R, Imhof H. Vertebral metastases: assessment with apparent diffusion coefficient. Radiology 2002; 225(3): 889-894.
90. Knight RA, Ordidge RJ, Helpern JA, Chopp M, Rodolosi LC, Peck D. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke 1991; 22(6): 802-808.
91. Le Bihan DJ. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the 'holy grail' of tissue characterization? Radiology 1998; 207(2): 305-307.
92. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int. 2009; 104(5): 621-627.
93. Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM, Dauser R, Pipe JG, Betley AT. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. Am. J. Neuroradiol. 1995; 16(2): 361-371.
94. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J. Chem. Phys. 1965; 42: 5.
95. Norris DG, Bornert P, Reese T, Leibfritz D. On the application of ultra-fast RARE experiments. Magn. Reson. Med. 1992; 27(1): 142-164.
96. Dietrich O, Raya JG, Sommer J, Deimling M, Reiser MF, Baur-Melnyk A. Diffusion-weighted MRI of musculoskeletal soft-tissue tumors using a RARE-based single-shot pulse sequence. Proceedings of the 13th Annual Meeting ISMRM, Miami, FL, USA, 2005; Vol. 2066.
97. Dietrich O, Raya JG, Sommer J, Deimling M, Reiser MF, Baur-Melnyk A. A comparative evaluation of a RARE-based single-shot pulse sequence for diffusion-weighted MRI of musculoskeletal soft-tissue tumors. Eur. Radiol. 2005; 15(4): 772-783.
98. Deng J, Miller FH, Salem R, Omary RA, Larson AC. Multishot diffusion-weighted PROPELLER magnetic resonance imaging of the abdomen. Invest. Radiol. 2006; 41(10): 769-775.
99. Deng J, Virmani S, Young J, Harris K, Yang GY, Rademaker A, Woloschak G, Omary RA, Larson AC. Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J. Magn. Reson. Imaging 2008; 27(5): 1069-1076.
100. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, Ludwig WD, Hamm B. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J. Magn. Reson. Imaging 2008; 27(5): 1109-1113.
101. Uhl M, Saueressig U, van Buiren M, Kontny U, Niemeyer C, Kohler G, Ilyasov K, Langer M. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest. Radiol. 2006; 41(8): 618-623.
102. Bley TA, Wieben O, Uhl M. Diffusion-weighted MR imaging in musculoskeletal radiology: applications in trauma, tumors, and inflammation. Magn. Reson. Imaging Clin. N. Am. 2009; 17(2): 263-275.
103. Oka K, Yakushiji T, Sato H, Hirai T, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol. 2010; 39(2): 141-146.
104. Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, Sakai Y, Saito K, Masuda H, Fujii Y, Kihara K. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75(2): 387-391.
105. Oka K, Yakushiji T, Sato H, Yorimitsu S, Hayashida Y, Yamashita Y, Mizuta H. Ability of diffusion-weighted imaging for the differential diagnosis between chronic expanding hematomas and malignant soft tissue tumors. J. Magn. Reson. Imaging 2008; 28(5): 1195-1200.
106. Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 2002; 62(5): 1555-1558.
107. Alibek S, Cavallaro A, Aplas A, Uder M, Staatz G. Diffusion weighted imaging of pediatric and adolescent malignancies with regard to detection and delineation: initial experience. Acad. Radiol. 2009; 16(7): 866-871.
108. 1H MR spectroscopy: initial results. Radiology 2004; 232(2): 599-605.
109. Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. J. Comput. Assist. Tomogr. 2008; 32: 8.
110. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann. N. Y. Acad. Sci. 1987; 508: 333-348.
111. Frahm J, Merboldt K-D, Haenicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 1987; 72: 502-508.
112. Moonen CT, von Kienlin M, van Zijl PC, Cohen J, Gillen J, Daly P, Wolf G. Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy. NMR Biomed. 1989; 2(5-6): 201-8.
113. Kassem MN, Bartha R. Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction. Magn. Reson. Med. 2003; 49(5): 918-927.
114. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001; 153(2): 155-177.
115. 1H MR spectroscopy in bone and soft tissue tumors. Chin. Med. J. (Engl.) 2009; 122(1): 39-43.
116. de Graaf RA. In Vivo NMR Spectroscopy: Principles and Techniques. John Wiley: West Sussex; 2007, p. 445.
117. de Graaf RA. In Vivo NMR Spectroscopy: Principles and Techniques. John Wiley: West Sussex; 2007, p. 111.
118. Ernst T, Kreis R, Ross BD. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J. Magn. Reson., Ser. B 1993; 102: 8.
119. Boesch C. Musculoskeletal spectroscopy. J. Magn. Reson. Imaging 2007; 25(2): 321-338.
120. Machann J, Stefan N, Schick F. (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. Eur. J. Radiol. 2008; 67(2): 275-284.
121. Boesch C, Machann J, Vermathen P, Schick F. Role of proton MR for the study of muscle lipid metabolism. NMR Biomed. 2006; 19(7): 968-988.
122. 1H MRS measurements of intramyocellular lipid in overweight and lean subjects under conditions of controlled dietary calorie and fat intake. NMR Biomed. 2008; 21(5): 498-506.
123. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell. Biochem. 2003; 90(3): 525-533.
124. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5(5): 303-324.
125. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12(7): 413-439.
126. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001; 3(1): 36-40.
127. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9): 3599-3603.
128. 1H magnetic resonance spectroscopy. Neoplasia 2006; 8(7): 560-567.
129. 1H MR spectroscopy. Radiology 2009; 251(3): 653-662.
130. Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J, Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin. Invest. Med. 2006; 29(5): 301-311.
131. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev. Mol. Diagn. 2006; 6(6): 821-829.
132. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7(7): 1109-1123.
133. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A, Apice G. Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res. 2005; 25(6C): 4519-4526.
134. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF. Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res. 2003; 9(6): 1941-1956.
135. 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 1996; 9(8): 347-358.
136. Griffiths JR. Are cancer cells acidic? Br. J. Cancer 1991; 64(3): 425-427.
137. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol. 1994; 267(1 Pt 1): C195-C203.
138. Arias-Mendoza F, Brown TR. In vivo phosphorus MR spectroscopy demonstrates the heterogeneous composition of sarcomas. Proceedings of the -19th Annual Meeting ISMRM, Montreal, QC, Canada, 2011; Vol. 3425.
139. Ojugo AS, McSheehy PM, McIntyre DJ, McCoy C, Stubbs M, Leach MO, Judson IR, Griffiths JR. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P probes. NMR Biomed. 1999; 12(8): 495-504.
140. Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng. Med. Biol. Mag. 2004; 23(5): 57-64.
141. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 2002; 94(5): 1557-1564.
142. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, Ross BD. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. USA 1999; 96(17): 9821-9826.
143. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin. Cancer Res. 2003; 9(14): 5101-5112.
144. Ballinger JR. Imaging hypoxia in tumors. Semin. Nucl. Med. 2001; 31(4): 321-329.
145. Padhani A. Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia? Radiology 2010; 254(1): 1-3.
146. Nitz WR, Reimer P. Contrast mechanisms in MR imaging. Eur. Radiol. 1999; 9(6): 1032-1046.
147. Robinson SP, Howe FA, Rodrigues LM, Stubbs M, Griffiths JR. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin. Radiat. Oncol. 1998; 8(3): 197-207.
148. 19F magnetic resonance imaging. Invest. Radiol. 1988; 23(5): 361-364.
149. Matsumoto S, Yasui H, Batra S, Kinoshita Y, Bernardo M, Munasinghe JP, Utsumi H, Choudhuri R, Devasahayam N, Subramanian S, Mitchell JB, Krishna MC. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc. Natl. Acad. Sci. USA 2009; 106(42): 17 898-17 903.
150. Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, Ruehm SG, Barkhausen J. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004; 233(1): 139-148.
151. Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, Matsumoto S, Kotani Y, Sugimura K. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008; 248(2): 643-654.
152. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat. Med. 2004; 22(4): 275-282.
153. Duewell SH, Ceckler TL, Ong K, Wen H, Jaffer FA, Chesnick SA, Balaban RS. Musculoskeletal MR imaging at 4 T and at 1.5 T: comparison of relaxation times and image contrast. Radiology 1995; 196(2): 551-555.
154. Gold GE, Han E, Stainsby J, Wright G, Brittain J, Beaulieu C. Musculoskeletal MRI at 3.0 T: relaxation times and image contrast. Am. J. Roentgenol. 2004; 183(2): 343-351.
155. Gold GE, Suh B, Sawyer-Glover A, Beaulieu C. Musculoskeletal MRI at 3.0 T: initial clinical experience. Am. J. Roentgenol. 2004; 183(5): 1479-1486.
156. Saupe N, Prussmann KP, Luechinger R, Bosiger P, Marincek B, Weishaupt D. MR imaging of the wrist: comparison between 1.5- and 3-T MR imaging - preliminary experience. Radiology 2005; 234(1): 256-264.